Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN ...

About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

“Our third quarter and recent period have been marked by outstanding progress in advancing our pipeline of CRISPR-based gene editing therapies,” said Intellia President and Chief Executive Officer ...

CAMBRIDGE, Mass. & MONTREAL, November 07, 2024 -- ( BUSINESS WIRE )--Repare Therapeutics Inc. ("Repare" or the "Company") ...

Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...

Final analysis from IGNITE Phase 2 clinical trial planned for first half of 2025: The Company plans to report the final analysis from the IGNITE Phase 2 clinical trial, including all patients at 12 ...

Key updated preliminary results from the Phase 3 ENLIGHTED study of Padeliporfin VTP: Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the ...

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 ...

Quarter Results07.11.2024 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic, Inc. Reports Third Quarter 2024 Financial Resultsand Provides Corporate Update– ...

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

Jupiter Neurosciences, Inc. (JUNS) is planning to raise $11 million in an initial public offering (IPO) on the week of November 11th, IPO Scoop reports. The company plans to issue 2,800,000 shares at ...